These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35433173)

  • 21. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
    Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrepancies in Wechsler Adult Intelligent Scale III profile in adult with and without attention-deficit hyperactivity disorder.
    Takeda T; Nakashima Y; Tsuji Y
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):166-174. PubMed ID: 32333645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    Osteoporos Int; 2021 May; 32(5):927-938. PubMed ID: 33118050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive use of nitisinone in alkaptonuria.
    Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ
    Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
    Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
    JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Phenylalanine- and Tyrosine-Restricted Diet in Alkaptonuria Patients on Nitisinone Treatment: Case Series and Review of Literature.
    Teke Kisa P; Eroglu Erkmen S; Bahceci H; Arslan Gulten Z; Aydogan A; Karalar Pekuz OK; Yuce Inel T; Ozturk T; Uysal S; Arslan N
    Ann Nutr Metab; 2022; 78(1):48-60. PubMed ID: 34736252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Norman BP; Bou-Gharios G; Gallagher JA; Gornall M; Jackson R; Imrich R; Rovensky J; Rudebeck M; Olsson B
    Mol Genet Metab Rep; 2022 Mar; 30():100846. PubMed ID: 35242577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Associations between cognitive performance in a dementia screening test (SKT) and an intelligence test (WAIS IV) : Which deficits in cognitive performance in old age indicate a possible pathological deterioration process?].
    Pauli L; Daseking M; Petermann F; Stemmler M
    Z Gerontol Geriatr; 2018 Apr; 51(3):266-274. PubMed ID: 28600610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of nitisinone in patients with alkaptonuria.
    Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
    Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.
    Stewart RM; Briggs MC; Jarvis JC; Gallagher JA; Ranganath L
    JIMD Rep; 2014; 17():1-6. PubMed ID: 24997710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features.
    Langford B; Besford M; Hall A; Eddowes L; Timmis O; Gallagher JA; Ranganath L
    JIMD Rep; 2018; 41():53-62. PubMed ID: 29654544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Wilson PJ; Dillon JP; West E; Gallagher JA
    JIMD Rep; 2020 Sep; 55(1):75-87. PubMed ID: 32904992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    J Inherit Metab Dis; 2021 May; 44(3):666-676. PubMed ID: 33452825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.
    Mistry JB; Jackson DJ; Bukhari M; Taylor AM
    Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.
    Griffin R; Psarelli EE; Cox TF; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA; Ranganath LR
    Data Brief; 2018 Oct; 20():1620-1628. PubMed ID: 30263914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.